Polypeptide to Showcase cGMP-Manufacturing Capability at InformEx 2014

Torrance, California: – Leading GMP peptide manufacturer Polypeptide Group will present its GMP compliant manufacturing capabilities at InformEx, the global chemical market exhibition, being held in Miami this month.

Polypeptide will also use its InformEx exhibition stand to showcase its huge range of research-grade peptides, stable and radio isotope-labelled peptides, Generic Peptides, and capacity for up to 100 kg+ GMP commercial manufacturing.

The group has access to a comprehensive catalogue of more than 1,250 bioactive peptides along with a more than 750 special amino acids and derivatives, building blocks and turn mimics, all available from stock.

The Polypeptide team at Booth 1044 at the Miami Beach Convention Centre also wants to engage Biotech leaders, large pharma companies and research-based organisations about the group’s capabilities as a contract manufacturer and as a global research peptide partner.

“We have a huge range of facilities, certification and expertise that we can bring to any peptide-based project,” said Polypeptide Account Manager Jeffrey Nelson. “We’re hoping to have many conversations at InformEx about ways in which we can add value to research or manufacturing.”

“We know from previous experience, most recently at the Anaheim show in 2012, what a great platform InformEx can provide for forging new connections and relationships”, said Mr. Nelson.

About Polypeptide Group
The PolyPeptide Group is a privately held company that one of the world’s leading therapeutic peptide manufacturing organisations with more than 50 years of experience. The Group employs 450 trained staff at six separate manufacturing sites in Denmark (Hillerød), France (Strasbourg), India (Mumbai), Sweden (Malmö) and the USA (San Diego and Torrance).

Peptide manufacturing services range from small-scale non-GMP custom synthesis for basic research and lead discovery, through support for pre-clinical studies and on to pre-GMP development of large-scale manufacturing processes. PolyPeptide Group cGMP manufactured peptide structures range from dipeptides up to the most complex structures for today’s therapeutic market, including conjugates with PEG, lipids, and non-peptidic components as well as peptides with multi-cyclic, branched, and substituted sequences.

The Group has more than 20 approved drug substances worldwide, including established generics such as Calcitonin, Desmopressin, Leuprolide and Octreotide, as well as a continually expanding range of new products including Eptifibatide, Bivalirudin, Exenatide and hPTH (1-34). The PolyPeptide Group also offers a full spectrum of complementary services for peptide projects, including a comprehensive catalogue of more than 1,250 bioactive peptides.

About InformEx
InformEx is a high prestige event that offers participants a direct view of what is happening globally across the fine, specialty and custom chemical markets. The event brings together an international mix of buyers and sellers of high value chemistry for four days of sourcing, education & networking. The 2014 event marks InformEx’s 30th birthday and is being held January 21-24, 2014 at the Miami Beach Convention Centre, Miami, Florida, USA.

More than 3,500 delegates and some 450 suppliers will attend the event, representing twelve different industry groups, including agrochemicals, life sciences and biotechnology, pharmaceuticals, petrochemicals and consumer goods.

The exhibition, organised by UBM Live, is complemented by a comprehensive conference program as well as extensive networking events.

Contact
Polypeptide USA
Jeffrey Nelson, Account Manager
Tel: +1 (310) 782-3569
Email: [email protected]

For more information about PolyPeptide to showcase cGMP-manufacturing capability at InformEx 2014, please contact PolyPeptide directly.